Share Prices & Company Research

Market News

15 Feb 2021 | 12:17

Sanofi Covid-19 vaccines may be ready by end of 2021

(Sharecast News) - French drug giant Sanofi's two vaccine candidates against Covid-19 may be ready by year-end, the company said, refuting an earlier report.



Both candidates were set to begin early-stage clinical trials in coming weeks and might be ready by the end of 2021, the head of Sanofi Pasteur, Thomas Triomphe, told Bloomberg.

The more advanced of those two vaccines, which Sanofi was working on jointly with GlaxoSmithKline was set to begin its second phase clinical trial later in February.

Earlier, French daily Journal du Dimanche had quoted the firm's boss, Paul Hudson, as saying that the so-called messenger RNA vaccine under development would not be ready by the end of 2021.

On 8 February, a company official had said it could be ready by the start of 2022 at the latest.

As of 1233 GMT, stock in Sanofi was trading 0.82% higher to €78.80.



Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 14th May 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.